UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $11.50 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 21.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 262,851 shares of the company's stock after buying an additional 46,825 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of Revolution Medicines worth $11,497,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. IFP Advisors Inc acquired a new position in Revolution Medicines in the 4th quarter valued at about $34,000. Sterling Capital Management LLC increased its position in shares of Revolution Medicines by 588.7% in the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Revolution Medicines by 368.3% in the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after purchasing an additional 1,613 shares in the last quarter. Kapitalo Investimentos Ltda purchased a new stake in shares of Revolution Medicines during the 4th quarter worth $104,000. Finally, Daiwa Securities Group Inc. grew its stake in shares of Revolution Medicines by 521.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after purchasing an additional 3,178 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company's stock.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 1,864 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares in the company, valued at approximately $4,489,834.24. This trade represents a 1.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark A. Goldsmith sold 11,738 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the transaction, the insider now owns 441,564 shares in the company, valued at $17,238,658.56. The trade was a 2.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock valued at $650,406 over the last quarter. Company insiders own 8.20% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on RVMD shares. Wedbush reissued an "outperform" rating and set a $67.00 price objective on shares of Revolution Medicines in a report on Thursday, May 8th. Oppenheimer increased their price target on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Guggenheim dropped their price objective on shares of Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and issued a $57.00 target price on shares of Revolution Medicines in a research note on Thursday, May 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $72.00 price target (down from $73.00) on shares of Revolution Medicines in a research note on Wednesday, May 14th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $67.08.

Revolution Medicines Trading Down 0.5%

NASDAQ:RVMD traded down $0.20 during midday trading on Wednesday, hitting $40.38. 1,468,982 shares of the stock were exchanged, compared to its average volume of 1,526,761. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $62.40. The company has a market capitalization of $7.52 billion, a price-to-earnings ratio of -11.25 and a beta of 1.11. The business has a 50-day moving average price of $37.73 and a two-hundred day moving average price of $41.60.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter last year, the company earned ($0.70) earnings per share. Sell-side analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.